Health Technology
Takeda Pharmaceutical Co., Ltd.
- 4,060.00 JPY
- -58.00
- -1.41%
Japan
Apr 22, 2019Ticker
TKS(4502)Prev. close
4,118Market cap (JPY)
6,444.69BMarket cap (USD)
57,601.05MShares
1,565.00M
In the news
- Japan's lopsided M&A boom Mar 4, 2019
- Takeda and rivals chase cancer therapy prize through M&A Jan 8, 2019
- Japan's MUFG extends $18bn loan to Bristol-Myers for megadeal Jan 5, 2019
- Asia's highest paid CEOs trump US execs in pay rankings Dec 19, 2018
- Takeda's stock sinks to 6-year low on debt concerns Dec 8, 2018 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 1,770.53B | 15,974.84M |
| Gross Profit | 1,148.86B | 10,365.80M |
| Operating income | 195,320M | 1,762.30M |
| Income before tax | 217,205M | 1,959.76M |
| Net income | 186,886M | 1,686.20M |
| EBITDA | 377,447M | 3,405.56M |
| Diluted EPS | 237.55 | 2.14 |
| Dividends Per Share | 180 | 1.62 |
| Total Assets | 4,106.46B | 38,612.71M |
| Total liabilities | 2,089.05B | 19,643.19M |
| Total equity | 1,997.42B | 18,781.60M |
| Operating cash flow | 379,600M | 3,424.99M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 1,691.68B | 1,777.82B | 1,807.37B | 1,732.05B | 1,770.53B |
| Gross Profit | 1,060.98B | 1,134.39B | 1,161.84B | 1,017.65B | 1,148.86B |
| Operating income | 145,604M | 195,804M | 175,770M | 86,972M | 195,320M |
| Income before tax | 158,851M | -145,437M | 120,542M | 143,346M | 217,205M |
| Net income | 106,658M | -145,775M | 80,166M | 114,940M | 186,886M |
| EBITDA | 332,856M | 387,391M | 353,275M | 258,398M | 377,447M |
| Diluted EPS | 134.95 | -185.37 | 101.71 | 146.25 | 237.55 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 4,569.14B | 4,296.19B | 3,824.08B | 4,346.79B | 4,106.46B |
| Total liabilities | 2,028.50B | 2,090.01B | 1,812.88B | 2,397.82B | 2,089.05B |
| Total equity | 2,470.73B | 2,137.04B | 1,948.69B | 1,894.26B | 1,997.42B |
| Operating cash flow | 148,335M | 183,441M | 26,552M | 260,067M | 379,600M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 16,887.88M | 16,183.14M | 15,050.91M | 15,994.93M | 15,974.84M |
| Gross Profit | 10,591.64M | 10,326.11M | 9,675.22M | 9,397.74M | 10,365.80M |
| Operating income | 1,453.54M | 1,782.36M | 1,463.72M | 803.15M | 1,762.30M |
| Income before tax | 1,585.79M | -1,323.88M | 1,003.81M | 1,323.75M | 1,959.76M |
| Net income | 1,064.75M | -1,326.95M | 667.58M | 1,061.43M | 1,686.20M |
| EBITDA | 3,322.86M | 3,526.33M | 2,941.89M | 2,386.22M | 3,405.56M |
| Diluted EPS | 1.34 | -1.68 | 0.84 | 1.35 | 2.14 |
| Dividends Per Share | 1.79 | 1.63 | 1.49 | 1.66 | 1.62 |
| Total Assets | 44,367.08M | 35,823.98M | 34,023.62M | 39,009.18M | 38,612.71M |
| Total liabilities | 19,697.13M | 17,427.69M | 16,129.56M | 21,518.70M | 19,643.19M |
| Total equity | 23,991.25M | 17,819.86M | 17,337.88M | 16,999.56M | 18,781.60M |
| Operating cash flow | 1,480.81M | 1,669.82M | 221.11M | 2,401.63M | 3,424.99M |
Valuation Measures
| Mar 2018 | |
| PER | 21.65 |
| ROA | 4.42% |
| ROE | 9.60% |
| Operating margin | 11.03% |
| Profit margin | 10.55% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer: Costa Saroukos
- Director, Chief Medical & Scientific Officer: Andrew S. Plump
- Executive Officer & Global General Counsel: Yoshihiro Nakagawa
- Global Human Resources Officer & Executive Officer: David Osborne
Shareholders
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
- BlackRock Fund Advisors (3.1%)
- Asset Management One Co., Ltd. (2.7%)
- Causeway Capital Management LLC (2.6%)
- Nippon Life Insurance Co. (2.6%)
- The Vanguard Group, Inc. (1.9%)
- Capital Research & Management Co. (World Investors) (1.7%)
- Nikko Asset Management Co., Ltd. (1.6%)
- State Street Global Advisors Ltd. (1.5%)
- Nomura Asset Management Co., Ltd. (1.5%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Takeda Consumer Healthcare Co. Ltd.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
- Takeda Mexico SA de CV
- Takeda Kazakhstan LLP
- Takeda Pharmaceuticals Korea Co., Ltd.
- Takeda Farmaceutica Espana SA
- Takeda Pharma Ltda.
- Takeda Distribuidora Ltda.
- Takeda Vaccines, Inc.
- Takeda Pharma SA
- Takeda Pharma Vertrieb GmbH & Co. KG
- Takeda (China) Holdings Co. Ltd.
Competitors
- Dr. Reddy's Laboratories Ltd.
- Sanofi
- Ipsen SA
- Green Cross Corporation
- Amgen Inc.
- Eli Lilly and Company
- Grifols, S.A. Class A
- MorphoSys AG
- Hypera S.A.
- Celgene Corporation
- JSC Kyivmedpreparat
- YungShin Global Holding Corp.
- Endo International Plc
- Assembly Biosciences, Inc.
- Gossamer Bio, Inc.
- RedHill Biopharma Ltd.
- Nektar Therapeutics
- Chimerix, Inc.
- Ironwood Pharmaceuticals, Inc. Class A
- Sangamo Therapeutics, Inc.
- Spectrum Pharmaceuticals, Inc.
- Peptron. Inc.
- BeiGene, Ltd.
- Galapagos NV
- Adverum Biotechnologies Inc
- Denali Therapeutics Inc.
- Protagonist Therapeutics, Inc.
- Reata Pharmaceuticals, Inc. Class A
- Voyager Therapeutics, Inc.
- Golden Biotechnology Corp.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 22 Apr, 2019